<SEC-DOCUMENT>0000950170-24-132452.txt : 20241203
<SEC-HEADER>0000950170-24-132452.hdr.sgml : 20241203
<ACCEPTANCE-DATETIME>20241203071004
ACCESSION NUMBER:		0000950170-24-132452
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241203
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241203
DATE AS OF CHANGE:		20241203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39926
		FILM NUMBER:		241521055

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tern-20241203.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-12-03T07:06:12.2721+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:tern="http://www.ternspharma.com/20241203" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_c244ac6f-483d-44e7-9f4d-fedaa1841c21" name="dei:AmendmentFlag" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9">false</ix:nonNumeric><ix:nonNumeric id="F_06cad748-6324-4a96-80bc-2f4504b5990f" name="dei:EntityCentralIndexKey" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9">0001831363</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="tern-20241203.xsd"/></ix:references><ix:resources><xbrli:context id="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001831363</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-03</xbrli:startDate><xbrli:endDate>2024-12-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_55bf4216-d484-42a9-8a06-e2f81d9f2dad" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_5e2b42ab-16ab-4145-beb4-97724899e563" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 03, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3838c09-2081-4135-b157-c125538c62bd" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Terns Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ac2c0e89-4bb6-4fa2-8709-9c450cc91afa" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_abd5fdac-dd5c-4b37-8052-284a18f46bc3" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39926</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_1e8d057d-189b-4035-bee0-ea8e86c57f84" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">98-1448275</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_759f590e-e215-43ed-9095-1cf7a966e154" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">1065 East Hillsdale Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_cdec8d0d-038a-46a7-844a-428284a5bfdf" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 100</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_24bc8e66-6b61-4b77-a644-185ef72688fb" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Foster City</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_d797dd51-93e7-4502-acde-b7f94bd5e2e2" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dfa1e831-e732-46e1-b842-78c7f51cfb87" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">94404</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_068110bf-8891-4776-9b35-2205da744537" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(650)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_dd848022-34c6-4a53-809a-80afa2c340b5" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">525-5535</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b76ac3e8-3b80-4c47-9fe1-cc648fafb791" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityInformationFormerLegalOrRegisteredName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">N/A</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88ad14f9-e5cf-4059-9638-1ebd60bc834b" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ebbf60a1-4c8d-4576-a18c-7091f7955f34" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25001a43-75d3-4bb7-8207-66edf77c3727" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7d267bc3-685b-4bec-b65b-0c27257053ab" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_dc7b9cc6-aa87-4665-b861-24239157c9e9" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8aaa9fc2-0b76-44a1-98a4-d4d11d12ee43" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">TERN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_32f88400-b1b2-472b-bc11-891bca3c697e" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ad19d983-f863-40b1-ae20-eb3b9f1db855" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;"><ix:nonNumeric id="F_ca4ba8f5-42ec-4880-a189-df3786508ff1" contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#231f20;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, 2024, Terns Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Terns&#8221;) issued a press release announcing encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory chronic myeloid leukemia (CML). A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 8.01 Other Events.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On December 3, 2024, Terns announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory CML. TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or without BCR-ABL resistance mutations who were previously treated with at least one 2G tyrosine kinase inhibitor (TKI). Patients previously treated with asciminib are also eligible.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Terns believes the emerging safety data show a profile supporting best-in-class potential with no dose limiting toxicities across three completed dose levels, no clinically meaningful changes in liver or pancreatic enzymes, and no AE-related dose reductions or discontinuations at doses that achieve plasma exposures well above target efficacious concentrations. Taken together, the clinical activity and safety data across the dose range in these heavily pre-treated patients with refractory disease support a potential wide therapeutic index that allows for high levels of target coverage with favorable safety/tolerability.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of the October 28, 2024 cutoff date, 15 patients were enrolled across three dose levels of 160mg (n=7), 320mg (n=5), and 400mg (n=3) of TERN-701 dosed once daily, with an overall median treatment duration of 3 months (range 0.79 - 7.5 months). Enrolled patients were heavily pretreated with a median of 4 prior TKIs (range: 1-6) and 80% having had 3 or more TKIs. 47% and 40% of patients, respectively, had previously received ponatinib and asciminib. 73% were not in MMR at baseline, with 60% having a baseline BCR-ABL transcript &gt;1% international scale (IS). As of the data cutoff, 14 of 15 patients remain on treatment.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Twelve patients were efficacy evaluable, defined as having baseline BCR-ABL transcript and at least two post-baseline BCR-ABL transcript levels (centrally assessed). All efficacy evaluable patients were in the 160mg and 320mg dose levels. Key efficacy highlights include:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">88% (7/8) of patients with baseline transcript &gt; 1% had decreases in BCR-ABL on treatment, with 7 ongoing as of data cutoff </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cumulative MMR rate of 50% (5/10) in non-T315i mutation patients with 3 or more months of treatment and/or MMR or better at baseline</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">100% (4/4) of patients with MMR or better at baseline have maintained their response and remain on treatment </span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional notable responses include:</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MR2 within 5 months in a 4L patient at 160mg QD with baseline transcript &gt; 1% and suboptimal response and intolerance to asciminib</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">MR4 (deep molecular response) within 3 months in a 5L patient treated at 320mg with baseline transcript &gt;10% and treatment failure on bosutinib at study entry</span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">TERN-701 showed a highly encouraging safety profile across the 160mg to 400mg dose levels, with 500mg undergoing evaluation as of data cutoff. Key safety highlights:</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No dose limiting toxicities (DLT) through 400mg dose level</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No adverse event (AE)-related treatment discontinuations or dose reductions</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No Grade 3 or higher treatment-related AEs</span></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">No treatment related serious AEs </span></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The incidence of treatment emergent hematologic AEs was notably low in this heavily pre-treated population, with no Grade 3 or higher treatment-related cytopenias. There were no non-hematologic treatment-related AEs more than Grade 2 in severity. Finally, no clinically meaningful changes in liver and pancreatic enzymes, blood pressure and other vitals, or electrocardiogram were seen.</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Steady state PK data, available for the 160mg and 320mg dose levels at data cutoff, showed linear PK with dose proportional increases in exposure. Plasma protein binding-corrected C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;min-width:fit-content;">average</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> for TERN-701 exceeded the in vitro IC90 for multiple mutated and non-mutated BCR-ABL variants with once daily dosing. Importantly, at 160mg and 320mg QD, TERN-701 achieved average free drug concentrations approximately 4-fold and 8-fold higher, respectively, than in vivo exposures where potent inhibition of the BCR-ABL signaling pathway in was seen in CML mouse tumor models, indicating robust pharmacodynamic effects at these clinical doses.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of December 3, 2024, the CARDINAL study has enrolled 19 patients inclusive of the 500mg cohort, with all dose escalation cohorts having enrolled at least 3 patients. The study is on track to initiate dose expansion in the first half of 2025 with additional efficacy data expected in the fourth quarter of 2025, including longer term MMR rates.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#111111;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">This Current Report on Form 8-K contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company&#8217;s small-molecule product candidates; the potential for the mechanisms of action of the Company&#8217;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#8217;s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company&#8217;s clinical trials; the Company&#8217;s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company&#8217;s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company&#8217;s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the potential commercialization of the Company&#8217;s product candidates; the Company&#8217;s plans and expectations around the addition of key personnel; and the Company&#8217;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company&#8217;s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;design,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;positioned,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#8217;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#8217;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company&#8217;s actual results, please refer to the risk factors identified in the Company&#8217;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.5%;box-sizing:content-box;"/>
    <td style="width:2.5%;box-sizing:content-box;"/>
    <td style="width:90%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">No.</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:1pt solid #000000;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="tern-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release issued by Terns Pharmaceuticals, Inc. on December 3, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0in;vertical-align:bottom;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">TERNS PHARMACEUTICALS, INC.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">December 3, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Elona Kogan</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;padding-bottom:0in;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Elona Kogan<br/>Chief Legal Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tern-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img52906712_0.jpg" alt="img52906712_0.jpg" style="width:155px;height:81px;"></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">High levels of target coverage achieved with once daily dosing at all doses</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Completion of dose escalation and initiation of dose expansion expected in 1H25</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Additional efficacy data expected in 4Q25, including longer term major molecular response (MMR) rates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Company to host webcast at 8:00 am ET today</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">FOSTER CITY, Calif., December 3, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (&#x201c;Terns&#x201d; or the &#x201c;Company&#x201d;) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced encouraging early data from the ongoing dose escalation part of the Phase 1 CARDINAL study evaluating TERN-701 in patients with relapsed/refractory chronic myeloid leukemia (CML).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-701 is an investigational, oral, potent, small molecule allosteric BCR-ABL inhibitor being developed for patients with CML. CARDINAL is a global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, pharmacokinetics (PK), and efficacy of TERN-701 in patients with relapsed/refractory CML with or without BCR-ABL resistance mutations who were previously treated with at least one 2G tyrosine kinase inhibitor (TKI). Patients previously treated with asciminib are also eligible.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;These exciting early data from our Phase 1 dose escalation cohorts clearly show TERN-701 has compelling clinical activity with a highly encouraging cumulative MMR rate of 50% at 3 months. At the first two dose levels, we see clinically meaningful molecular and hematologic responses in patients with high baseline BCR-ABL transcript levels who had poor responses on prior 2G TKIs, 3G TKIs including ponatinib, as well as asciminib,&#x201d; said Emil Kuriakose MD, chief medical officer of Terns.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;The emerging safety data show a profile supporting best-in-class potential with no dose limiting toxicities across three completed dose levels, no clinically meaningful changes in liver or pancreatic enzymes, and no AE-related dose reductions or discontinuations at doses that achieve plasma exposures well above target efficacious concentrations. Taken together, the clinical activity and safety data across the dose range in these heavily pre-treated patients with refractory disease support a potential wide therapeutic index that allows for high levels of target coverage with favorable safety/tolerability.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We are thrilled to share these impactful early data from the Phase 1 CARDINAL study of TERN-701, which support its potential to be a best-in-class allosteric inhibitor for the treatment of CML,&#x201d; said Amy Burroughs, chief executive officer of Terns. &#x201c;In addition to the meaningful clinical data, the CARDINAL study highlights yet another example of excellent clinical and operational execution at Terns, with patients enrolled in all four dose escalation cohorts in less than a year. We are well-positioned to initiate dose expansion cohorts in the first half of 2025 and look forward to sharing additional safety and efficacy data, including longer term MMR data in late 2025.&#x201d;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.9in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of the October 28, 2024 cutoff date, 15 patients were enrolled across three dose levels of 160mg (n=7), 320mg (n=5), and 400mg (n=3) of TERN-701 dosed once daily, with an overall median treatment duration of 3 months (range 0.79 - 7.5 months). Enrolled patients were heavily pretreated with a median of 4 prior TKIs (range: 1-6) and 80% having had 3 or more TKIs. 47% and 40% of patients, respectively, had previously received ponatinib and asciminib. 73% were not in MMR at baseline, with 60% having a baseline BCR-ABL transcript &gt;1% international scale (IS). As of the data cutoff, 14 of 15 patients remain on treatment.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Twelve patients were efficacy evaluable, defined as having baseline BCR-ABL transcript and at least two post-baseline BCR-ABL transcript levels (centrally assessed). All efficacy evaluable patients were in the 160mg and 320mg dose levels. Key efficacy highlights include:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">88% (7/8) of patients with baseline transcript &gt; 1% had decreases in BCR-ABL on treatment, with 7 ongoing as of data cutoff </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cumulative MMR rate of 50% (5/10) in non-T315i mutation patients with 3 or more months of treatment and/or MMR or better at baseline</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">100% (4/4) of patients with MMR or better at baseline have maintained their response and remain on treatment </font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Additional notable responses include:</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">MR2 within 5 months in a 4L patient at 160mg QD with baseline transcript &gt; 1% and suboptimal response and intolerance to asciminib</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">MR4 (deep molecular response) within 3 months in a 5L patient treated at 320mg with baseline transcript &gt;10% and treatment failure on bosutinib at study entry </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">TERN-701 showed a highly encouraging safety profile across the 160mg to 400mg dose levels, with 500mg undergoing evaluation as of data cutoff. Key safety highlights:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No dose limiting toxicities (DLT) through 400mg dose level</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No adverse event (AE)-related treatment discontinuations or dose reductions</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No Grade 3 or higher treatment-related AEs</font></div></div>
  <div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">No treatment related serious AEs </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The incidence of treatment emergent hematologic AEs was notably low in this heavily pre-treated population, with no Grade 3 or higher treatment-related cytopenias. There were no non-hematologic treatment-related AEs more than Grade 2 in severity. Finally, no clinically meaningful changes in liver and pancreatic enzymes, blood pressure and other vitals, or electrocardiogram were seen.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Steady state PK data, available for the 160mg and 320mg dose levels at data cutoff, showed linear PK with dose proportional increases in exposure. Plasma protein binding-corrected C</font><font style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">average</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> for TERN-701 exceeded the in vitro IC90 for multiple mutated and non-mutated BCR-ABL variants with once daily dosing. Importantly, at 160mg and 320mg QD, TERN-701 achieved average free drug concentrations approximately 4-fold and 8-fold higher, respectively, than </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">in vivo</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> exposures where potent inhibition of the BCR-ABL signaling pathway in was seen in CML mouse tumor models, indicating robust pharmacodynamic effects at these clinical doses.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">As of December 3, 2024, the CARDINAL study has enrolled 19 patients inclusive of the 500mg cohort, with all dose escalation cohorts having enrolled at least 3 patients. The study is on track to initiate dose expansion in the first half of 2025 with additional efficacy data expected in the fourth quarter of 2025, including longer term MMR rates.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.9in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Company Webcast</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns will host a company webcast at 8:00 am ET today. The discussion will cover TERN-701&#x2019;s Phase 1 interim data, next steps for the CARDINAL program, and TERN-701&#x2019;s potential role in the CML treatment landscape.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The event will be webcast live and can be accessed by visiting the investor relations section of the Company&#x2019;s website at https://ir.ternspharma.com. An archived webcast will be available following the event.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About CARDINAL</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The CARDINAL trial is an ongoing global, multicenter, open-label, two-part Phase 1 clinical trial to evaluate the safety, PK, and efficacy of TERN-701 in patients with previously treated CML. Part 1 is the dose escalation portion of the trial evaluating once-daily TERN-701 monotherapy in up to five dose cohorts in up to 60 adults with chronic phase CML with confirmed BCR-ABL and a history of treatment failure or suboptimal response to at least one second generation TKI (nilotinib, dasatinib or bosutinib). Participants who are intolerant to prior TKI treatment (including asciminib) are also allowed. The primary endpoints for Part 1 are the incidence of DLTs during the first treatment cycle, and additional measures of safety and tolerability. Secondary endpoints include TERN-701 PK and efficacy assessments, such as hematologic and molecular responses as measured by the change from baseline in BCR-ABL transcript levels. The starting dose is 160 mg QD (once-daily) with dose escalations as high as 500 mg QD and the option to explore a lower dose of 80 mg QD. Part 2 is the dose expansion portion of the trial that will enroll approximately 40 patients, randomized to once-daily treatment with one of two doses of TERN-701 to be selected based on data from Part 1. The primary endpoint of the dose expansion portion of the trial is efficacy, measured by hematologic and molecular responses. Secondary endpoints include safety, tolerability and PK. The overall objective of the CARDINAL trial is to select the optimal dose(s) of TERN-701 to move forward to a potential pivotal trial in chronic phase CML.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Terns Pharmaceuticals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns&#x2019; pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-&#x3b2; agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: </font><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">www.ternspharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.9in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:0.9in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cautionary Note Regarding Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">This press release contains forward-looking statements about the Company within the meaning of the federal securities laws, including those related to expectations, timing and potential results of the clinical trials and other development activities of the Company and its partners; the potential indications to be targeted by the Company with its small-molecule product candidates; the therapeutic potential of the Company&#x2019;s small-molecule product candidates; the potential for the mechanisms of action of the Company&#x2019;s product candidates to be therapeutic targets for their targeted indications; the potential utility and progress of the Company&#x2019;s product candidates in their targeted indications, including the clinical utility of the data from and the endpoints used in the Company&#x2019;s clinical trials; the Company&#x2019;s clinical development plans and activities, including the results of any interactions with regulatory authorities on its programs; the Company&#x2019;s expectations regarding the profile of its product candidates, including efficacy, tolerability, safety, metabolic stability and pharmacokinetic profile and potential differentiation as compared to other products or product candidates; the Company&#x2019;s plans for and ability to continue to execute on its current development strategy, including potential combinations involving multiple product candidates; the potential commercialization of the Company&#x2019;s product candidates; the Company&#x2019;s plans and expectations around the addition of key personnel; and the Company&#x2019;s expectations with regard to its cash runway and sufficiency of its cash resources. All statements other than statements of historical facts contained in this press release, including statements regarding the Company&#x2019;s strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company&#x2019;s plans to vary materially, including the risks associated with the initiation, cost, timing, progress, results and utility of the Company&#x2019;s current and future research and development activities and preclinical studies and clinical trials. These risks are not exhaustive. For a detailed discussion of the risk factors that could affect the Company&#x2019;s actual results, please refer to the risk factors identified in the Company&#x2019;s SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Contacts for Terns</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investors</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Justin Ng</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">investors@ternspharma.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#ff0000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Media</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Jenna Urban</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Berry &amp; Company Public Relations</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#0563c1;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">media@ternspharma.com</font><font style="color:#ff0000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.9in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img52906712_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img52906712_0.jpg
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MX9#_V@ , P$  A$#$0   ;_
M
M
M
M
M
M                          #I.77%'8ZB'6STL0-GIO.>[%L,TTDM_C4S
MY'SZ                         !YUNXU^?OSL\?*[+HRNTQ\KG=60
M(YYNL@[MM#![;:&&^STN'=O0 !=?%9U<S&)L
M !Y]N8Y7+=OFN)ED4]_.?6/IQY=ET979]&5V71E=ECY/9=&5V71E=ICY?88^
M7VG3D=GCY79=&5V?1E>N1J93"K&ZHY2^OX\RV!\3J[N)U]O=8^7(/6;GL<?+
MSS12GT_3R                          >)R2'5TW%YYC+853<S(Q/[]^
M  <'JR.=VXX $I:]MGG=7?$RQZ? X&/E^BPZPI^U#Z F?"++YO#L
M                  'B.]B]?MH4E$JRJ;Y^UT7W[>D #&<':9-G:L  6 TS
MZ+K^N;SI^>//.8W,;$Z3](S!@-J_3YR                            &
M&Y>!"&=UA#RR*=\IFE;]OFZ[]\N'PX=GD\>F'K\DA8  L IGT5!BVZ$G]2WH
MZ=53WQSNKO                               \TV6FBW-*X\&G%:1EW4
M>C'C;"1]A4^ !ZA'Y7852WH_WR&V'G.IWX
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M/0NR!IUV92UW\4G=IL>ENG)9M*VNQZ774Q6<QLS]7JU6!5&Q]![,L'TTC
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M#$"1Y#DF*=\1T.>32^@              !CV;K:&/8/Y\WJ^1??F9ZO>
M   "MOXF:0R.28J=^8T9N>$?'OGUA7QE_P!<LRX\"^/7/K&B;9X6>;G#/0CP
MSX['ZSX[4\1+2OH               8]FZVJ;T3Y&MZ\T^RP       /@?<^
M!\CDGP/L<8^A^3[GS.*<XX1S#KCM3Y'\.(<L^IQ3Y'W/F<X
M  &/9NMC//*MES6UR                                     #K>_%_
M+YVG1E@
M
M
M
M
M
M                        #__:  @! 0 !!0+_ !KKW)N:R7O/N+&.GOJW
M0AIYZE,HNET>=<KH3<>=49*U04:4>5\54RV-(SPS")CM:21X5K.[3>K*4PK^
MRD.1B&*I!GG)P1/^4,\NXEQ<@7'[/2[D50H^+/\ %V23)Y5B1\9JO_J^@1"
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MKO\ ;%K=ZLF6=O-6EJAAK9D7%^J*O_I.."*^%<-PK=%?F2G?$98!7#\)+3(
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M4[8ZJ1F31R2"T$@WV18YR!2_DV XDY[#=%?>0H]GU%(0:Y#*I:"!,$%.0
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MQQ[P#Z^(?XV*F&0T@DT'$&6P#V/_ #W_ /_:  P# 0 "$0,1   0
M
M
M
M
M
M                                                       #>'
M                         "BS     _NMMN
M    'YM_(?J%:*J")[@                          =]MMM%MMYMI.
M                        %5=MMUMMLJ#H
M    % ,N5MMJ'                                *EMMM90
M                          =MM@  .VVX.VQ'VVH!0 . 66
M     -ML8  MMMPUMN&MM=%4 I#-N               -MI   K=# W;>&;9
MJ%J I3NL0              -MH    %0 QDD&$DD%% IP[
M  -M4    %0 UMN&MMK%Q.I'U7               -M     %0 S;;&+00%V
M)I K58              -M(    %0 Q  &8%(%PEA0X3P              -
ML     %0 S '&8&$%P$I%,T(              -L     '( O_\ 0J , "!&
MQ?[0              #;@                                    #6
M                                    #2       !(%$@(, !@(-$@@
M               #2       !,   H@(I,)(I)                #
M     )  ) (! !!((                #P
M            +P
M
M
M
M
M
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M;P+1-,%]6)%2"(R4# ;3Q(A$P$/T1!)?='$VLD M(MBF  M34*DE"KQ57^W
MKU\9P*:.7K'CD%2XZT>$[4ER;(#C[=P-J^P>"_ZA3JH"258L@I9RFM[ZGQ+[
M/.#D-[KWJ-.I.[0;HZJ]93SX @G@D03@&HW P&=$/)9HN<G;4DT!3/H9G0*D
M&G(S9TD9!!Q_HH%?OD_M+Q]G4A'C @0$2R(@>$U>BE)'ACZA)&C#R %0&*=Q
M X4W-9Y"B[SO!?66_=J2GZKY,J6L&A>9]N_J?$OL\X.0P"258D I91K>D;5]
M@\$_U*G7+]U[A CAI^R$P@,A5 (8O-V]"%G?![2,6D\^1Q(03Z$@6]/, @_
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M3Y^B'IMB[1C=X&#.O&] *0;2@R /ZQ"JKINCE>F66FY]M2L;L"O<R'0T#8(
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>tern-20241203.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-12-03T07:06:12.9012+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.ternspharma.com/20241203" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tern="http://www.ternspharma.com/20241203" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tern-20241203.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Information, Former Legal or Registered Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInformationFormerLegalOrRegisteredName" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInformationFormerLegalOrRegisteredName" xlink:label="dei_EntityInformationFormerLegalOrRegisteredName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10200.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInformationFormerLegalOrRegisteredName" order="10150.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45868577736624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 03, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  03,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Terns Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001831363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1448275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1065 East Hillsdale Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Foster City<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">525-5535<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationFormerLegalOrRegisteredName', window );">Entity Information, Former Legal or Registered Name</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TERN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationFormerLegalOrRegisteredName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Former Legal or Registered Name of an entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationFormerLegalOrRegisteredName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M#2BN^%/PO3XZ)G8H*RF_VI.':.1XEHC'/#16@L'7CD]Y'%LEX/AV$'6J>]K
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $$Y@UDZJJ+G0 $  #P"   /
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M-Y-;2>C@W(-@[^&5C!W-CQ]W]P-02P,$%     @ 03F#620>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( $$Y@UEED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !!.8-9A.GB6>T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !!.8-9
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( $$Y@UG4\/=INP0  ) 2   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !!.8-9
MGZ ;\+$"  #B#   #0              @ ']#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( $$Y@UF7BKL<P    !,"   +              "  =D/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( $$Y@UDZJJ+G0 $  #P"   /
M      "  <(0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !!.8-9)!Z;
MHJT   #X 0  &@              @ $O$@  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !!.8-999!YDAD!  #/ P  $P
M    @ $4$P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  !>
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="tern-20241203.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tern-20241203.htm">tern-20241203.htm</File>
    <File>tern-20241203.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tern-20241203.htm": {
   "nsprefix": "tern",
   "nsuri": "http://www.ternspharma.com/20241203",
   "dts": {
    "inline": {
     "local": [
      "tern-20241203.htm"
     ]
    },
    "schema": {
     "local": [
      "tern-20241203.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 25,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 26,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 25
   },
   "report": {
    "R1": {
     "role": "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20241203.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tern-20241203.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Information, Former Legal or Registered Name",
        "documentation": "Former Legal or Registered Name of an entity"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.ternspharma.com/20241203/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-132452-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-132452-xbrl.zip
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MJ!4),#UT1>I3+F!4_XH9_HYBGA,Q;;Z4](Y./LY"9/[C=_6CV=[' +",U;^
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M"&,TF %RL%[\M"7#<U IX0T\ SVLE/(;.FFD>9>XUFNY K2%@:%\_GR.C"\
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MSSUEQQKF^V63ZD2 2 =$P=<O!)<_JIGOV@@O)+Z1([@2?#_(V?]02P,$%
M  @ 03F#63ODP7 8&   3)    \   !T97)N+65X.3E?,2YH=&WM76MWVS:3
M_O[^"FQZW-<^1Y(EV8IM*>U9QW%;;RYU$^_I[J<]$ E)B$F"!4C+ZJ_?F0%
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M7'>86W"4R&U_0&W7W3ENQ:K/-FBNAJ SGDQP5OUN?T#S2)2ZQE6:<UUQ$3E
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M*YEU]Z$!OA7FO8^YGXZQ@IH7O]\((3[3+JZ4CJUC9\OQ^:2?>RN+=_GRK]3
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MW:O*79OJDG5GN5V-QJ)Z;SV'$5BQ]@*%<^)/7*%6[72C60)X *SO"TW5D5H
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M;BTR,#(T,3(P,RYH=&U02P$"% ,4    " !!.8-98!G3]OL(  !F:0  $0
M            @ $Z(@  =&5R;BTR,#(T,3(P,RYX<V102P$"% ,4    " !!
M.8-9.^3!<!@8  !,D   #P              @ %D*P  =&5R;BUE>#DY7S$N
9:'1M4$L%!@     #  , NP   *E#      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>tern-20241203_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tern-20241203.xsd" xlink:type="simple"/>
    <context id="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001831363</identifier>
        </entity>
        <period>
            <startDate>2024-12-03</startDate>
            <endDate>2024-12-03</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_c244ac6f-483d-44e7-9f4d-fedaa1841c21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_06cad748-6324-4a96-80bc-2f4504b5990f">0001831363</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_55bf4216-d484-42a9-8a06-e2f81d9f2dad">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_5e2b42ab-16ab-4145-beb4-97724899e563">2024-12-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_b3838c09-2081-4135-b157-c125538c62bd">Terns Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_ac2c0e89-4bb6-4fa2-8709-9c450cc91afa">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_abd5fdac-dd5c-4b37-8052-284a18f46bc3">001-39926</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_1e8d057d-189b-4035-bee0-ea8e86c57f84">98-1448275</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_759f590e-e215-43ed-9095-1cf7a966e154">1065 East Hillsdale Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_cdec8d0d-038a-46a7-844a-428284a5bfdf">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_24bc8e66-6b61-4b77-a644-185ef72688fb">Foster City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_d797dd51-93e7-4502-acde-b7f94bd5e2e2">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_dfa1e831-e732-46e1-b842-78c7f51cfb87">94404</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_068110bf-8891-4776-9b35-2205da744537">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_dd848022-34c6-4a53-809a-80afa2c340b5">525-5535</dei:LocalPhoneNumber>
    <dei:EntityInformationFormerLegalOrRegisteredName
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_b76ac3e8-3b80-4c47-9fe1-cc648fafb791">N/A</dei:EntityInformationFormerLegalOrRegisteredName>
    <dei:WrittenCommunications
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_88ad14f9-e5cf-4059-9638-1ebd60bc834b">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_ebbf60a1-4c8d-4576-a18c-7091f7955f34">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_25001a43-75d3-4bb7-8207-66edf77c3727">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_7d267bc3-685b-4bec-b65b-0c27257053ab">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_dc7b9cc6-aa87-4665-b861-24239157c9e9">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_8aaa9fc2-0b76-44a1-98a4-d4d11d12ee43">TERN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_32f88400-b1b2-472b-bc11-891bca3c697e">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_ad19d983-f863-40b1-ae20-eb3b9f1db855">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_bae0b6ef-4100-46e5-b5f1-e74c9f8f1cc9"
      id="F_ca4ba8f5-42ec-4880-a189-df3786508ff1">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
